Biologics in Severe Asthma: From Precision Phenotyping to Clinical Remission - PubMed
5 hours ago
- #biologic-therapies
- #clinical-remission
- #severe-asthma
- Biologic therapies for severe asthma show significant efficacy in reducing exacerbation rates (26% to 56% vs. placebo).
- They also reduce oral corticosteroid dependence and improve lung function and quality of life.
- Biomarkers like blood eosinophils, FeNO, and serum IgE are crucial for treatment selection.
- Clinical remission, including symptom freedom and no exacerbations, is achievable in 32% to 50% of patients.
- Tezepelumab is effective in a broader population, including those with lower T2 inflammation.
- The management of severe asthma has shifted to precision medicine based on molecular phenotyping.
- Future research should focus on non-type 2 asthma therapies and refining dynamic biomarkers.